Last edition
News about "Bent Jakobsen"
Accession Therapeutics Doses First Patient in Phase 1 Trial of TROCEPT-01
Accession Therapeutics has dosed the first patient in its Phase 1 trial of TROCEPT-01 (ATTR-01), a first-in-class tumour-activated viral immunotherapy. Designed for systemic delivery, the therapy aims to selectively generate a checkpoint inhibitor within tumours, offering a targeted approach to cancer treatment.
Bent Jakobsen | 18/11/2025 | By Dineshwori
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members